Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma (CSSG-03)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04042597
Recruitment Status : Unknown
Verified August 2019 by Peking University People's Hospital.
Recruitment status was:  Recruiting
First Posted : August 2, 2019
Last Update Posted : August 5, 2019
Sponsor:
Collaborators:
Peking University Shougang Hospital
Peking University Third Hospital
Peking University First Hospital
Beijing Jishuitan Hospital
Chinese PLA General Hospital
Peking University Cancer Hospital & Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Information provided by (Responsible Party):
Peking University People's Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. Anlotinib is a novel tyrosine kinase inhibitor targeting both at VEGFR-2, -3 and PDGFRA and PDGFRB with high affinity, which also showed broad antitumor activity against EGFR and so on. Thus this multicenter, two-armed phase II trial of PKUPH-sarcoma 05 intended to investigate the efficacy and safety of anlotinib versus imatinib on advanced chordoma.

Condition or disease Intervention/treatment Phase
Effect of Drugs Quality of Life Chordoma Advanced Cancer Drug: Anlotinib Hydrochloride Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicentre, Open-label, Randomised Phase 2 Trial to Study the Efficacy and Safety of Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
Actual Study Start Date : July 18, 2019
Estimated Primary Completion Date : October 30, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Chordoma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A: anlotinib arm
anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
 Drug: Anlotinib Hydrochloride
anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
Active Comparator: Arm B: imatinib arm
Imatinib was given at dose of 400 mg twice daily continuously
 Drug: Anlotinib Hydrochloride
anlotinib was given at a fixed dose of 12mg D1-14 every 21 days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Objective response rate, ORR [ Time Frame: 6 months ]
    CR+PR in the intent-to-treat population according to RECIST, version 1.1

  2. Progression-free Survival, PFS [ Time Frame: 2 years ]
    Progression-free survival is defined as time from randomisation to the first occurrence of progression of disease or death from any cause within 63 days of last response assessment or randomisation


Secondary Outcome Measures :
  1. Overall Survival, OS [ Time Frame: 5 years ]
    OS is defined as time from randomisation to the first occurrence of death from any cause within 63 days of last response assessment or randomisation.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years and older;
  • histologically proven metastatic or locally advanced chordoma, reviewed by the Pathology Committee of Peking University People's Hospital;
  • not amenable to curative-intent surgery;
  • measurable with computed tomography scan or magnetic resonance imaging, per RECIST, version 1.1.

Exclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG)30 performance status more than 2 ;
  • life expectancy less than 12 weeks;
  • with severe or uncontrolled medical disorders (≥grade 2 of Common Terminology Criteria for Adverse Events version 4.03 [CTCAE version 4.03]) that could jeopardise the outcomes of the study, for example, cardiac clinical symptom or disease with LVEF (left ventricular ejection fraction) <50%, hypertension that could not be well controlled through antihypertensive drugs and so on;
  • weight loss of 20% or more before illness;
  • brain or leptomeningeal metastasis;
  • surgical procedure or radiotherapy within 4 weeks of enrollment;
  • active gastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation;
  • proteinuria or hematuria;
  • denutrition with albuminemia less than 25 g/L;
  • pregnant or breastfeeding status;
  • other malignancy, positive HBV/HCV/HIV serology;
  • known allergy to the experimental agents;
  • had ever used anti-angiogenesis TKIs.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04042597


Contacts
Layout table for location contacts
Contact: Lu Xie, M.D. +8613401044719 xie.lu@hotmail.com
Contact: Jie Xu, M.D. +8615901040835 xujie_pkuph@sina.com

Locations
Layout table for location information
China, Beijing
Peking University People's Hospital Recruiting
Beijing, Beijing, China, 100044
Contact: Tingting Ren, Ph. D.    +861380095026    tumorcenter@163.com   
Sponsors and Collaborators
Peking University People's Hospital
Peking University Shougang Hospital
Peking University Third Hospital
Peking University First Hospital
Beijing Jishuitan Hospital
Chinese PLA General Hospital
Peking University Cancer Hospital & Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Investigators
Layout table for investigator information
Principal Investigator: Wei Guo, M.D. and Ph.D. Musculoskeletal Tumor Center of Peking University People's Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Peking University People's Hospital
ClinicalTrials.gov Identifier: NCT04042597    
Other Study ID Numbers: PKUPH-sarcoma 05
First Posted: August 2, 2019    Key Record Dates
Last Update Posted: August 5, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Peking University People's Hospital:
chordoma
unresectable
anlotinib
 imatinib
survival
quality of life
Additional relevant MeSH terms:
Layout table for MeSH terms
Chordoma
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms